Hesse Reiterates Buy on Sixt After Strong Q1, Reaffirms FY26 Guidance and Maintains $110 Price Target
XLK ETF Rises 0.5%
XLK ETF Falls 1.2%
XLK ETF Declines 0.2%
XLK ETF Climbs 0.2%
XLK ETF Gains 0.3%
XLK ETF Closes Flat
Did U.S. stocks escape the “September curse”? Goldman Sachs warns: an October hurricane is approaching.
Sheng predicts that U.S. equities will face tests from earnings reports and macroeconomic risks in October, with market volatility expected to rise. The actual volatility in October is more than 25% higher than in other months.
Powerfleet Secures Partnership With SIXT Mexico To Advance Digital Vehicle Rental Operations Via Unity's AIoT
EconomyBookings.com Announces Winners of Its 2025 Best Rated Supplier Award
Inflation cooling solidifies the expectation of Fed rate cuts! Will this industry become the new darling of Wall Street?
The SPDR S&P Biotech ETF (XBI) has achieved five consecutive gains, with a cumulative increase of nearly 8% in 5 days.
"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?
Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.
Popular Tech-sector ETF Could See Major Shakeup as Apple, Microsoft and Nvidia Jockey for Position
When will the sell-off in US stocks end? The top three technical analysts are here to guide the puzzle!
The three senior technical analysts are surprisingly in agreement: the sell-off is temporary, and the bottom may wait until this point to surface...
Liu Yuhui of Tianfeng Securities: Judging the current situation is very simple, just two subject words
There's never been a shortage of money in the stock market; what it really wants is risk appetite.